Neuroactive steroids and PTSD treatment

Neuroscience Letters

Volumn 649, Issue , 2017, Pages 156-163

  Rasmusson, Ann M ^a,b,c   Marx, Christine E ^d   Pineles, Suzanne L ^a,c   Locci, Andrea ^e   Scioli Salter, Erica R ^b,c   Nillni, Yael I ^a,c   Liang, Jennifer J ^c   Pinna, Graziano ^e  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

3 hydroxysteroid dehydrogenase; 5 Reductase type I and type 2; Allopregnanolone; Cortisol; Dehydroepiandrosterone; Endocannabinoids; GABAA receptors; Neuroactive steroids; Posttraumatic stress disorder (PTSD); Pregnanolone; Selective brain steroidogenic stimulants (SBSSs); TSPO ligands

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BREXANOLONE; ELTANOLONE; ESTRADIOL; GLUCOCORTICOID; NEUROACTIVE STEROID; PRASTERONE; STEROID; UNCLASSIFIED DRUG;

CLINICAL STUDY; COPING BEHAVIOR; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; POSTTRAUMATIC STRESS DISORDER; PRECLINICAL STUDY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; ANIMAL; COMPLICATION; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DEHYDROEPIANDROSTERONE; ESTRADIOL; GLUCOCORTICOIDS; HUMANS; PREGNANOLONE; STEROIDS; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL;

EID: 85014634857     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2017.01.054     Document Type: Review

References (112)

1. [1] Rasmusson, M., The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr. 8 (2003), 651–667.
2. [2] Pitman, A.M., Rasmusson, K.C., Koenen, L.M., Shin, S.P., Orr, M.W., Gilbertson, M.R., Biological studies of post-traumatic stress disorder. Nat. Rev. Neurosci. 13 (2012), 769–787.
3. [3] Witchel, S.F., Lee, P.A., Suda-Hartman, M., Trucco, M., Hoffman, E.P., Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-Hydroxylase deficiency 1. J. Clin. Endocrin. Metab. 82 (1997), 2097–2101.
4. [4] Sellini, M., Sartori, M.P., Baccarini, S., Bassi, R., Dimitriadis, E., ACTH and cortisol after cigarette smoke exposure during the dexamethasone suppression test in smokers and non-smokers. Bollettino della Società italiana di biologia sperimentale, 65, 1989, 377.
5. [5] Yehuda, S.L., Halligan, R., Grossman, J.A., The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder. Biol. Psychiatry 52 (2002), 393–403.
6. [6] Logue, A.K., Baldwin, C., Wolf, G., Guffanti, A., Ratanatharathorn, A., Stone, S.A., Schichman, D., Humphries, E.B., Arloth, J., An analysis of gene expression in PTSD implicates genes involved in the glucocorticoid receptor pathway and neural responses to stress. Psychoneuroendocrinology 57 (2015), 1–3.
7. [7] Klengel, D., Mehta, C., Rex-Haffner, J.C., Pruessner, C.M., Pariante, T.W., Pace, K.B., Mercer, H.S., Mayberg, B., Bradley, C.B., Nemeroff, F., Holsboer, C.M., Heim, K.J., Ressler, T., Binder, E.B., Nat. Neurosci. 16 (2013), 33–41 http://www.ncbi.nlm.nih.gov/pubmed/23201972.
8. [8] Gourley, A.T., Kedves, P., A history of corticosterone exposure regulates fear extinction and cortical NR2B, GluR2/3, and BDNF. Neuropsychopharmacology 34 (2009), 707–716.
9. [9] A.R. Gutman, Y., Yang, K.J., Ressler, M. Davis, The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci. 28 (2008), 12682–12690.
10. [10] Hou, Y.T., Lin, H.K., Penning, T.M., Dexamethasone regulation of the rat 3 hydroxysteroid/dihydrodiol dihydrogenase (3-HSD/DD) gene. Mol. Pharmacol. 53 (1998), 459–466.
11. [11] Jovanovic, J.E., Phifer, K., Sicking, T., Weiss, S.D., Norrholm, B., Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 36 (2011), 1540–1552.
12. [12] Schelling, E., Kilger, B., de Quervain, J., Briegel, A., Rothenhausler, B.T., Krauseneck, G., Kapfhammer, H.P., Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiat. 55 (2004), 627–633.
13. [13] Zohar, J., Yahalom, H., Kozlovsky, N., Cwikel-Hamzany, S., Matar, M.A., Kaplan, Z., Yehuda, R., Cohen, H., High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies. Eur. Neuropsychopharm. 21 (2011), 796–809.
14. [14] Sawamura, T., Klengel, A., Armario, T., Jovanovic, S.D., Norrholm, K.J., Dexamethasone treatment leads to enhanced fear extinction and dynamic Fkbp5 regulation in amygdala. Neuropsychopharmacology 41 (2016), 832–846.
15. [15] Cai, J., Blundell, J., Han, R.W., Postreactivation glucocorticoids impair recall of established fear memory. J. Neurosci. 26 (2006), 9560–9566.
16. [16] Dennis, M.K., Bura, R., Ramesh, C., Petrie, W.K., Alcon, S.N., Nayak, T.K., Bologa, C.G., Leitao, A., Brailoiu, E., Deliu, E., Dun, N.J., In vivo effects of a GPR30 antagonist. Nature Chem. Biol. 5 (2009), 421–427, 10.1038/nchembio.168.
17. [17] Prossnitz, E.R., Arterburn, J.B., Smith, H.O., Oprea, T.I., Sklar, L.A., Hathaway, H.J., Estrogen signaling through the transmembrane G protein-coupled receptor GPR 30. Annu. Rev. Physiol., 2008, 165–190, 10.1146/annurev.physiol.70.113006.100518.
18. [18] Lebron-Milad, K., Milad, M.R., Sex differences, gonadal hormones and the fear extinction network: implications for anxiety disorders. Biol. Mood Anxiety Disord. 2 (2012), 1–12.
19. [19] Pineles, S.L., Nillni, Y.I., King, M.W., Patton, S.C., Bauer, M.R., Mostoufi, S.M., Gerber, M.R., Hauger, R., Resick, P.A., Rasmusson, A.M., Orr, S.P., Extinction retention and the menstrual cycle: different associations for women with posttraumatic stress disorder. J. Abnormal Psychol., 125, 2016, 349.
20. [20] Ressler, K.J., Mercer, K.B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., Norrholm, S.D., Kilaru, V., Smith, A.K., Myers, A.J., Ramirez, M., Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470 (2011), 492–497.
21. [21] Rasmusson, A.M., Pinna, G., Paliwal, P., Weisman, D., Gottschalk, C., Charney, D., Krystal, J., Guidotti, A., Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biol. Psychiatry 60 (2006), 704–713.
22. [22] Mitev, M., Darwish, S.S., Wolf, F., Holsboer, O.F., Gender differences in the regulation of 3α-hydroxysteroid dehydrogenase in rat brain and sensitivity to neurosteroid-mediated stress protection. Neuroscience 120 (2003), 541–549.
23. [23] Zukowska-Grojec, Z., Chrousos, G.P., McCarty, R., Pacák, K., et al, Neuropeptide Y: A novel sympathetic stress hormone. Stress: Basic mechanisms and clinical implications, 771, 1995, New York Academy of Sciences, New York, NY, 219–233 (In Eds.).
24. [24] Yehuda, R., Brand, S., Yang, R.K., Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry, 2006, 660–663, 10.1016/j.biopsych.2005.08.027.
25. [25] Yehuda, R., Pratchett, L.C., Elmes, M.W., Lehrner, A., Daskalakis, N.P., Koch, E., Makotkine, I., Flory, J.D., Bierer, L.M., Glucocorticoid-related predictors and correlates of post-traumatic stress disorder treatment response in combat veterans. Interface Focus, 4(5), 2014, 20140048, 10.1098/rsfs.2014.0048.
26. [26] Frokjaer, V.G., Erritzoe, D., Juul, A., Nielsen, F.A., Holst, K., Svarer, C., Madsen, J., Paulson, O.B., Knudsen, G.M., Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding. Psychoneuroendocrinology 35 (2010), 1311–1320.
27. [27] Mann, J.J., Arango, V., Marzuk, P.M., Theccanat, S., Reis, D.J., Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br. J. Psychiatry 8:Suppl (1989), 7–14.
28. [28] Hrdina, P.D., Demeter, E., Vu, T.B., Sotonyi, P., Palkovits, M., 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res. 614 (1993), 37–44.
29. [29] Vermeire, S., Audenaert, K., De Meester. Vandermeulen, R.E., Waelbers De Spiegeleer, T.B., Eersels, J., Dobbeleir, A., Peremans, K., Neuro-imaging the serotonin 2A receptor as a valid biomarker for canine behavioral disorders. Res. Vet. Sci. 91 (2011), 465–472.
30. [30] Rosell, D.R., Thompson, J.L., Slifstein, M., Xu, X., Frankll. New, W.G.A.S., Goodman, M., Weinstein, S.R., Laruelle, M., Abi-Dargham, A., Siever, L.J., Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol. Psychiatry 2010:67 (2010), 1154–1162.
31. [31] Weisstaub, N.V., Zhou, M., Lira, A., Lambe, E., González-Maeso, J., Hornung, J.P., Sibille, E., Underwood, M., Itohara, S., Dauer, W.T., Ansorge, M.S., Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science, 2006, 536–540, 10.1126/science.1123432.
32. [32] Southwick, S.M., Krystal, J.H., Bremner, J.D., Morgan, C., Nicolaou, A.L., Nagy, L.M., Johnson, D.R., Heninger, G.R., Charney, D.S., Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 54 (1997), 749–758.
33. [33] Harada, K., Yamaji, T., Matsuoka, N., Activation of the serotonin 5-HT2C receptor is involved in the enhanced anxiety in rats after single-prolonged stress. Pharmacol. Biochem. Behav. 89 (2008), 11–16.
34. [34] Anderson, D.J., Optogenetics, sex, and violence in the brain: implications for psychiatry. Biol. Psychiatry 71 (2011), 1081–1089.
35. [35] Biegon, A., Alia-Klein, N., Fowler, J.S., Potential contribution of aromatase inhibition to the effects of nicotine and related compounds on the brain. Front. Pharmacol., 3, 2012, 10.3389/fphar.2012.00185.
36. [36] Koenen, K.C., Hitsman, B., Lyons, M.J., Niaura, R., McCaffery, J., Goldberg, J., Eisen, S.A., True, W., Tsuang, M., A twin registry study of the relationship between posttraumatic stress disorder and nicotine dependence in men. Arch. Gen. Psychiatry 62 (2005), 1258–1265.
37. [37] Japuntich, S.J., Gregor, K., Pineles, S.L., Gradus, J.L., Street, A.E., Prabhala, R., Rasmusson, A.M., Deployment stress, tobacco use, and postdeployment posttraumatic stress disorder: gender differences. Psychol. Trauma: Theory Res. Pract. Policy, 8, 2016, 123.
38. [38] Mattson, M.P., Robinson, N., Guo, Q., Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. Neuroreport 8 (1997), 3817–3821.
39. [39] Wang, J., Green, P.S., Simpkins, J.W., Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J. Neurochem. 77 (2001), 804–811.
40. [40] Keller, J.N., Germeyer, A., Begley, J.G., Mattson, M.P., 17β-Estradiol attenuates oxidative impairment of synaptic Na+/K + -ATPase activity, glucose transport, and glutamate transport induced by amyloid β-peptide and iron. J. Neurosci. Res. 50 (1997), 522–530, 10.1002/(SICI)1097-4547(19971115)50:4<522::AID-JNR3>3. 0. CO; 2-G.
41. [41] Bryant, D.N., Dorsa, D.M., Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity. Neuroscience (2010) 170 (2010), 1261–1269, 10.1016/j.neuroscience.2010.08.019.
42. [42] Du, L., Bayir, H., Lai, Y., Zhang, X., Kochanek, P.M., Watkins, S.C., Graham, S.H., Clark, R.S., Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J. Biol. Chem. 279 (2004), 38563–38570, 10.1074/jbc.M405461200.
43. [43] Zhao, L., Yao, J., Mao, Z., Chen, S., Wang, Y., Brinton, R.D., 17β-Estradiol regulates insulin degrading enzyme expression via an ER(/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol. Aging 32 (2011), 1949–1963, 10.1016/j.neurobiolaging.2009.12.010.
44. [44] Rasmusson, A., P450 enzyme blocks in the progesterone GABAergic neuroactive steroid synthesis pathway in PTSD: sex differences. 2nd Neurosteroid Congress, Durham, North Carolina April 6–8, 2016.
45. [45] Dong, E., Matsumoto, K., Uzunova, V., Sugaya, I., Takahata, H., Nomura, H., Watanabe, H., Costa, E., Guidotti, A., Brain 5alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. 98 (2001), 2849–2854.
46. [46] Zhang, L.M., Qiu, Z.K., Zhao, N., Chen, H.X., Liu, Y.Q., Xu, J.P., Zhang, Y.Z., Yang Li, R.F.Y.F., Anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder. Int. J. Neuropsychopharm. 17 (2014), 1659–1669.
47. [47] Pinna, G., Costa, E., Guidotti, A., Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 2135–2140.
48. [48] Gillespie, C.F., Almli, L.M., Smith, A.K., Bradley, B., Kerley, K., Crain, D.F., Mercer, K.B., Weiss, T., Phifer, J., Tang, Y., Cubells, J.F., Sex dependent influence of a functional polymorphism in steroid 5- α- reductase type 2 (SRD5A2) on post-traumatic stress symptoms. Am. J. Med. Genetics Part B: Neuropsychiatr. Genet. 162 (2013), 283–292.
49. [49] Purdy, A.L., Morrow, P.H., Stress-induced elevations of gamma amino butyric acid type A receptor-active steroids in the rat brain. Proc. Nat. Acad. Sci. 88:10 (1991), 4553–4557.
50. [50] Agís-Balboa, R.C., Pinna, G., Zhubi, A., Maloku, E., Veldic, M., Costa, E., Guidotti, A., Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc. Nat. Acad. Sci. 103 (2006), 14602–14607.
51. [51] Semyanov, A., Walker, M.C., Kullmann, D.M., Silver, R.A., Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci. 27 (2004), 262–269.
52. [52] Calza, A., Sogliano, C., Santoru, F., Marra, C., Angioni, M.M., Mostallino, M.C., Biggio, G., Concas, A., Neonatal exposure to estradiol in rats influences neuroactive steroid concentrations, GABAA receptor expression, and behavioral sensitivity to anxiolytic drugs. J. Neurochem. 113 (2010), 1285–1295.
53. [53] Calza, A., Sogliano, C., Santoru, F., Marra, C., Angioni, M.M., Mostallino, M.C., Biggio, G., Concas, A., Neonatal exposure to estradiol in rats influences neuroactive steroid concentrations, GABAA receptor expression, and behavioral sensitivity to anxiolytic drugs. J. Neurochem. 113 (2010), 1285–1295.
54. [54] Concas, A., Mostallino, M.C., Porcu, P., Follesa, P., Barbaccia, M.L., Trabucchi, M., Purdy, R.H., Grisenti, P., Biggio, G., Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type. A receptor in rat brain during pregnancy and after delivery. Proc. Natl. Acad. Sci. 95 (1998), 13284–13289.
55. [55] Follesa, P., Cagetti, E., Mancuso, L., Biggio, F., Manca, A., Maciocco, E., Massa, F., Desole, M.S., Carta, M., Busonero, F., Sanna, E., Biggio, G., Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res. Mol. Brain Res. 92 (2001), 138–148.
56. [56] Maguire, B.M., Stell, M., Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat. Neurosci. 8 (2005), 797–804.
57. [57] Morrow, A.L., Montpied, P., Paul, S.M., GABAA receptor function and expression following chronic ethanol and barbiturate administration. Ann. N. Y. Acad. Sci. 625 (1991), 496–507.
58. [58] Serra, M., Mostallino, M.C., Talani, G., Pisu, M.G., Carta, M., Mura, M.L., Floris, I., Maciocco, E., Sanna, E., Biggio, G., Social isolation-induced increase in alpha and delta subunit gene expression is associated with a greater efficacy of ethanol on steroidogenesis and GABA receptor function. J. Neurochem. 98 (2006), 122–133.
59. [59] Porcu, M.C., Mostallino, C., Sogliano, F., Santoru, R., Long-term administration with levonorgestrel decreases allopregnanolone levels and alters GABA(A) receptor subunit expression and anxiety-like behavior. Pharmacol. Biochem. Behav. 102:2 (2012), 366–372.
60. [60] Shen, H., Gong, Q.H., Aoki, C., Yuan, M., Ruderman, Y., Dattilo, M., Williams, K., Smith, S.S., Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty. Nat. Neurosci. 10 (2007), 469–477.
61. [61] Chhatwal, K.M., Ressler, K.J., Davis, M., Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J. Neurosci. 25 (2005), 502–506.
62. [62] Pinna, G., Rasmusson, A.M., Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder. Front. Cell. Neurosci., 8, 2014, 256.
63. [63] Pibiri, F., Nelson, M., Guidotti, A., Costa, E., Pinna, G., Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proceedings of the National Academy of Sciences. 2008 Apr 8 205:14 (2008), 5567–5572.
64. [64] Izumi, Y., O'Dell, K.A., Zorumski, C.F., Metaplastic LTP inhibition after LTD induction in CA1 hippocampal slices involves NMDA receptor-mediated neurosteroidogenesis. Physiol. Rep., 1, 2013, e00133.
65. [65] Park-Chung, M., Wu, F.S., Purdy, R.H., Malayev, A.A., Gibbs, T.T., Farb, D.H., Distinct sites for inverse modulation of N-Methyl-D-Aspartate receptors by sulfated steroids. Mol. Pharmacol. 52 (1997), 1113–1123.
66. [66] Gibbs, T.T., Russek, S.J., Farb, D.H., Sulfated steroids as endogenous neuromodulators Pharmacol. Biochem. Behav. 84 (2006), 555–567.
67. [67] Smith, T.T., Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology (Berl.) 231 (2014), 3537–3556.
68. [68] Malayev, A., Gibbs, T.T., Farb Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 135 (2002), 901–909.
69. [69] Bullock, A.E., Clark, A.L., Grady, S.R., Robinson, S.F., Slobe, B.S., Marks, M.J., Collins, A.C., Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J. Neurochem. 68 (1997), 2412–2423.
70. [70] Rupprecht, R., di Michele, F., Hermann, B., Ströhle, A., Lancel, M., Romeo, E., Holsboer, F., Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev. 37 (2001), 59–67.
71. [71] Pinna, G., Costa, E., Guidotti, A., SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr. Opin. Pharmacol. 9 (2009), 24–30.
72. [72] Uzunova, V., Sheline, Y., Davis, J.M., Rasmusson, A., Uzunov, D.P., Costa, E., Guidotti, A., Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Nat. Acad. Sci. 95 (1998), 3239–3244.
73. [73](a) Griffin, L.D., Mellon, S.H., Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Nat Acad. Sci. 96 (1999), 13512–13517.
74. [73](b) Trauger, J.W., Jiang, A., Stearns, B.A., LoGrasso, P.V., Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemi 41 (2002), 13451–13459.
75. [74] Schüle, C., Eser, D., Baghai, T.C., Nothdurfter, C., Kessler, J.S., Rupprecht, R., Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?. Neuroscience 191 (2011), 55–77.
76. [75] Sripada, R.K., Marx, C.E., King, J.C., Rampton, S.S., Liberzon, I., Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol. Psychiatry 73 (2013), 1045–1053.
77. [76] Sripada, R.K., Welsh, R.C., Marx, C.E., Liberzon, I., The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting-state amygdala connectivity. Hum. Brain Mapp. 35 (2014), 3249–3261.
78. [77] Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Reggio, P.H., Ross, R.A., Marsicano, G., Piazza, P.V., PV, Pregnenolone can protect the brain from cannabis intoxication. Science 343 (2014), 94–98.
79. [78] Stern, C.A., Gazarini, L., Takahashi, R.N., Guimarães, F.S., Bertoglio, L.J., On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 37 (2012), 2132–2142.
80. [79] Jenniches, I., Ternes, S., Albayram, O., Otte, D.M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., Zimmer, A., Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol. Psychiatry 79 (2016), 858–868.
81. [80] Lisboa, S.F., Reis, D.G., da Silva, A.L., Corrêa, F.M., Guimarães, F.S., Resstel, L.B., Cannabinoid [1CB] receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning. Int. J. Neuropsychopharmacol. 13:9 (2010), 1163–1173.
82. [81] Sasso, O., Russo, R., Vitiello, S., Raso, G.M., D'Agostino, G., Iacono, A., La Rana, G., Vallée, S., Piazza, P.V., Meli, R., Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain. Pain 153 (2012), 33–41.
83. [82] Yu, H.L., Deng, X.Q., Li, Y.J., Li, Y.C., Quan, Z.S., Sun, X.Y., N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. Pharmacol. Rep. 63 (2011), 834–839.
84. [83] Ghoumari, A.M., Ibanez, C., El-Etr, M., Leclerc, P., Eychenne, B., O'Malley, B.W., Baulieu, E.E., Schumacher, M., Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem. 86 (2003), 848–859.
85. [84] Ghoumari, A.M., Baulieu, E.E., Schumacher, M., Progesterone increases oligo-dendroglial cell proliferation in rat cerebellar slice cultures. Neuroscience 135 (2005), 47–58.
86. [85] Djebaili, M., Guo, Q., Pettus, E.H., Hoffman, S.W., Stein, D.G., The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J. Neurotrauma 22 (2005), 106–118.
87. [86] VanLandingham, J.W., Cekic, M., Cutler, S., Hoffman, S.W., Stein, D.G., Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci. Lett. 425 (2007), 94–98.
88. [87] Wang, J.M., Liu, L., Irwin, R.W., Chen, S., Brinton, R.D., Regenerative potential of allopregnanolone. Brain Res. Rev. 57 (2008), 398–409.
89. [88] Chalbot, S., Morfin, R., Dehydroepiandrosterone metabolites and their interactions in humans. Drug Metabol. Drug Interact. 22 (2006), 1–23.
90. [89] Balazs, Z., Schweizer, R.A., Frey, F.J., Rohner-Jeanrenaud, F., Odermatt, A., A. DHEA induces 11-HSD2 by acting on CCAAT/enhancer-binding proteins. J. Am. Soc. Nephrol. 19 (2008), 92–101.
91. [90] Park-Chung, M., Malayev, A., Purdy, R.H., Gibbs, T.T., Farb, D.H., Sulfated and unsulfated steroids modulate γ-aminobutyric acid A receptor function through distinct sites. Brain Res. 830 (1999), 72–87.
92. [91] Yehuda, R., Brand, S.R., Golier, J.A., Yang, R.K., Clinical correlates of DHEA associated with post-traumatic stress disorder. Acta Psychiatrica Scand. 114 (2006), 187–193.
93. [92] Genazzani, A.D., Stomati, M., Bernardi, F., Pieri, M., Rovati, L., Genazzani, A.R., Long-term low dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertility Sterility 80 (2003), 1495–1501.
94. [93] Dor, R.B., Marx, C.E., Shampine, L.J., Rubinow, D.R., Schmidt, P.J., DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. Psychopharmacology (Berl.) 232 (2015), 3375–3383.
95. [94] Marx, C.E., Naylor, J.C., Kilts, J.D., Dunn, C.E., Tupler, L.A., Szabo, S.T., Capehart, B.P., Morey, R.A., Shampine, L.J., Acheson, S.K., Laskowitz, D., Grant, G., Neurosteroids and traumatic brain injury: translating biomarkers to therapeutics; Overview and pilot Investigations in Iraq and Afghanistan era Veterans. Translational Research in Traumatic Brain Injury, 2016, CRC. Press/Taylor and Francis Group, Boca Raton (FL) (Chapter 7).
96. [95] Kilts, J.D., Tupler, L.A., Keefe, F.J., Payne, V.M., Hamer, R.M., Naylor, J.C., Calnaido, R.P., Morey, R.A., Strauss, J.L., Parke, G., Massing, M.W., Youssef, N.A., Shampine, L.J., Neurosteroids and self-reported pain in veterans who served in the US military after September 11, 2001. Pain Med. 11 (2010), 1469–1476.
97. [96] Naylor, J.C., Kilts, J.D., Strauss, J.L., Szabo, S.T., Dunn, C.E., Wagner, H.R., Hamer, R.M., Shampine, L.J., Zanga, J.R., Marx, C.E., An exploratory pilot investigation of neurosteroids and selfreported pain in female Iraq/Afghanistan-era Veterans. J. Rehab. Res. Dev., 53, 2016, 499.
98. [97] Scioli-Salter, E., Forman, D.E., Tun, C., Allsup, K., Marx, C.E., Hauger, R.L., Tyzik, A., Rasmusson, A.M., Potential neurobiological benefits of exercise in chronic pain and posttraumatic stress disorder: pilot study. J. Rehab. Res. Dev., 53, 2016, 95.
99. [98] Sofuoglu, M., Mouratidis, M., Mooney, M., Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology 36 (2011), 123–132.
100. [99] Brown, E.S., Park, J., Marx, C.E., Hynan, L.S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., Lo, A., Holmes, T., A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology 39 (2014), 2867–2873.
101. [100] Osuji, I.J., Vera-Bolaños, E., Carmody, T.J., Brown, E.S., Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res. 178 (2010), 309–312.
102. [101] C.E. Marx, J. Lee, M. Subramaniam, A. Rapisarda, Bautista, D.C., Chan, E., Kilts, J.D., Buchanan, R.W., Wai, E.P., Verma, S., Sim, K., Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl.) 231 (2014), 3647–3662.
103. [102] Calhoun, P.S., Stechuchak, K.M., Strauss, J., Bosworth, H.B., Marx, C.E., Butterfield, M.I., Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia. Schizophrenia Res. 91 (2007), 210–216.
104. [103] Meltzer-Brody, et al. ClinicalTrials.gov Identifier: NCT02614547. 2016.
105. [104] Herper, M., Experimental Drug Eliminates Postpartum Depression in 7 Out of 10 Patients. 2016, Forbes (Accessed 2016) http://www.forbes.com/sites/matthewherper/2016/07/12/experimental-drugdramatically-reduces-post-partum-depression-in-small-study/#4f6f8eab7aa3.
106. [105] Muzik, M., McGinnis, E.W., Bocknek, E., Morelen, D., Rosenblum, K.L., Liberzon, I., Seng, J., Abelson, J.L., PTSD symptoms across pregnancy and early postpartum among women with lifetime PTSD diagnosis. Depress. Anxiety 33 (2016), 584–591.
107. [106] Girdler, P.A., Straneva, K.C., Light, C.A., Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psychiatry 49 (2001), 788–797.
108. [107] Nillni, D., Anxiety sensitivity, the menstrual cycle, and panic disorder A putative neuroendocrine and psychological interaction. Clin. Psychol. Rev. 31 (2011), 1183–1191.
109. [108] Lovick, T., SSRIs and the female brain–potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias. J. Psychopharm. 27 (2013), 1180–1185.
110. [109] Brunton, P.J., Russell, J.A., Hirst, J.J., Allopregnanolone in the brain: protecting pregnancy and birth outcomes. Prog. Neurobiol. 113 (2014), 106–136.
111. [110] Pilver, C.E., Levy, B.R., Libby, D.J., Desai, R.A., Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Arch. Women's Mental Health 14 (2001), 383–393.
112. [111] K.A. Yonkers, M.V., Smith, A., Forray, C.N., Epperson, D., Costello, H., Lin, K. Belanger, Pregnant women with posttraumatic stress disorder and risk of preterm birth. JAMA Psychiatry, 2017.